Table 1.
Characteristics of the whole cohort of 122 patients who underwent allo-HSCT
| (n = 122) | |
|---|---|
| Age at transplant, median (range) | 58 (20–71) |
| Males, n (%) | 70 (57.3) |
| Haematological disease (%) | |
| AML | 63 (51.6) |
| ALL | 12 (9.8) |
| Lymphomas | 17 (13.9) |
| MDS | 6 (4.9) |
| MPNs | 16 (13.1) |
| MM | 4 (3.3) |
| SAA | 2 (1.6) |
| CLL | 2 (1.6) |
| Disease status, n (%) | |
| Remission (CR1, CR2, MRD±) | 72 (59) |
| Other than remission (PR1, PR2, SD) | 50 (41) |
| Comorbidity | |
| HCT-CI risk score, n (%) ≥ 3 | 44 (36.1) |
| Donor’s compatibility, n (%) | |
| Sibling donor | 34 (28) |
| Haploidentical donor | 34 (28) |
| Unrelated donor ≥8/8 | 40 (33) |
| Unrelated donor <8/8 | 14 (11) |
| Haemopoietic stem cells source, n (%) | |
| PBSC | 69 (56.5) |
| BM | 48 (39.4) |
| PBSC + BM | 5 (4) |
| Major AB0 incompatibility, n (%) | 21 (17.2) |
| Conditioning regimen, n (%) | |
| MAC | 85 (69.6) |
| MAC + TBI | 10 (8.2) |
| RIC | 28 (23) |
| nMAC | 9 (7.4) |
| GVHD prophylaxis, n (%) | |
| CsA/FK506 + MTX | 76 (62.3) |
| CsA/FK506 + ptCy | 45 (36.7) |
| CsA + MMF | 1 (0.8) |
| ATG | 69 (56) |
AML, acute myeloid leukemia; ALL acute lymphoid leukemia; MDS, myelodysplastic syndrome; MPNs, myeloproliferative neoplasms; MM, multiple myeloma; SAA, severe aplastic anemia; CLL, chronic lymphatic leukemia; CR, complete remission; MRD, minimal residual disease; PR, partial remission; PBSC, peripheral blood stem cell; BM, bone marrow; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; nMAC, non-myeloablative conditioning; GVHD, graft-versus-host disease; CsA, cyclosporine A; MTX, methotrexate; ptCy, post-transplant cyclophosphamide; MMF, mycophenolate mofetil; ATG, antithymocyte globulin; TBI, total body irradiation.